AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12755970 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative protective measures (limited exposure during peak sun hours, use of shade, protective clothing and hats)
Number of subjects: 360
Study 11224990 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 0
Study 11224990 — intervention group
Group type: EXPERIMENTAL
Intervention: New chemotherapeutic agents
Number of subjects: 0
Study 11224990 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological agents
Number of subjects: 0
Study 9507382 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-volume leukapheresis (LVL)
Number of subjects: 32
Study 7984977 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-lactam antibiotics for 10 days
Number of subjects: 54
Study 2499172 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Work Evaluation
Number of subjects: 201
Study 2499172 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 201
Study 18962621 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 4731
Study 18962621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4731
Study 106746 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cromoglycate
Number of subjects: 32
Study 106746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 30700318 — intervention group
Group type: EXPERIMENTAL
Intervention: ProYouth plus a structured dissonance‐based module
Number of subjects: 309
Study 30700318 — intervention group
Group type: EXPERIMENTAL
Intervention: ProYouth plus a CBT‐based chat group intervention
Number of subjects: 309
Study 30700318 — intervention group
Group type: COMPARATOR
Intervention: ProYouth (active control condition)
Number of subjects: 309
Study 26700792 — intervention group
Group type: EXPERIMENTAL
Intervention: DPREMB‐R morning score
Number of subjects: 0
Study 27072812 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaired tendons at 3 months
Number of subjects: 23
Study 27072812 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaired tendons at 6 months
Number of subjects: 23
Study 27072812 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaired tendons at 12 months
Number of subjects: 23
Study 27072812 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon core at 3 months
Number of subjects: 23
Study 27072812 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon core at 6 months
Number of subjects: 23
Study 27072812 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRS at 6 months
Number of subjects: 23
Study 25010793 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 3
Study 25010793 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 200 mg
Number of subjects: 3
Study 25010793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 22731733 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate brief cessation intervention
Number of subjects: 214
Study 22731733 — intervention group
Group type: COMPARATOR
Intervention: Delayed brief cessation intervention
Number of subjects: 214
Study 18834673 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalated radiation and concurrent temozolomide
Number of subjects: 26
Study 18834673 — intervention group
Group type: COMPARATOR
Intervention: Inadequate PET-GTV coverage
Number of subjects: 26
Study 17846260 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 186
Study 17846260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 15236782 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid 250 mg twice daily for seven days
Number of subjects: 40
Study 15236782 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 40
Study 15236782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12049858 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg, starting postoperatively
Number of subjects: 2309
Study 12049858 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg, starting preoperatively
Number of subjects: 2309
Study 12049858 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 2309
Study 12049858 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 2309
Study 9804592 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.2 microgram/kg iv)
Number of subjects: 62
Study 9804592 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 62
Study 9804592 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (0.15 mg/kg iv)
Number of subjects: 62
Study 9804592 — intervention group
Group type: COMPARATOR
Intervention: Air exposure
Number of subjects: 62
Study 8983937 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule formulation of thiocolchicoside (8 mg)
Number of subjects: 8
Study 8983937 — intervention group
Group type: COMPARATOR
Intervention: Tablet formulation of thiocolchicoside (8 mg)
Number of subjects: 8
Study 2654967 — intervention group
Group type: EXPERIMENTAL
Intervention: amitriptyline
Number of subjects: 21
Study 2654967 — intervention group
Group type: EXPERIMENTAL
Intervention: pirlindol
Number of subjects: 21
Study 794665 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydergin (3 mg daily)
Number of subjects: 51
Study 794665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 29756693 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-parametric pGDT
Number of subjects: 140
Study 29756693 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 140
Study 28489046 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroMini Motionlogger® Actigraph
Number of subjects: 0
Study 25816031 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk restraint group (TRG) - reaching training with trunk restraint
Number of subjects: 20
Study 25816031 — intervention group
Group type: COMPARATOR
Intervention: Trunk free group (TFG) - unrestraint reaching
Number of subjects: 20
Study 23640314 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbopelvic belt plus information
Number of subjects: 105
Study 23640314 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based pelvic stabilizing exercises plus information
Number of subjects: 105
Study 23640314 — intervention group
Group type: COMPARATOR
Intervention: Information alone (Control group)
Number of subjects: 105
Study 21939822 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 699
Study 19370821 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric IOL (Tecnis Z9000)
Number of subjects: 20
Study 19370821 — intervention group
Group type: COMPARATOR
Intervention: Spherical IOL (AcrySof SA60AT)
Number of subjects: 20
Study 17110814 — intervention group
Group type: EXPERIMENTAL
Intervention: STS 6 mg/24 h
Number of subjects: 322
Study 17110814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 15322328 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil (PGE(1), Prostavasin, intravenous, infusion rate: 0.38 microg/h/kg)
Number of subjects: 16
Study 15322328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11285377 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 7.5 mg daily over 2 years
Number of subjects: 28
Study 11285377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11285377 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 28
Study 9314456 — intervention group
Group type: EXPERIMENTAL
Intervention: Aplisol
Number of subjects: 51
Study 9314456 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubersol
Number of subjects: 51
Study 9314456 — intervention group
Group type: COMPARATOR
Intervention: Aplisol and Tubersol
Number of subjects: 51
Study 8212108 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets
Number of subjects: 0
Study 8212108 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis
Number of subjects: 0
Study 3537815 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical radical mastectomy by Halsted
Number of subjects: 816
Study 3537815 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy by Patey
Number of subjects: 816
Study 3537815 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative operation of radical resection type
Number of subjects: 816
Study 31482684 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin nanomicelle (40 mg, 3 times a day for 12 weeks)
Number of subjects: 65
Study 31482684 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 times a day for 12 weeks)
Number of subjects: 65
Study 31482684 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin nanomicelle
Number of subjects: 65
Study 31482684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 28187466 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Mangifera indica fruit powder
Number of subjects: 11
Study 28187466 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg Mangifera indica fruit powder
Number of subjects: 11
Study 28187466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 26133902 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM), standardized extract of 7 selected ingredients, 5 capsules twice daily for 8 weeks.
Number of subjects: 125
Study 26133902 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM)
Number of subjects: 125
Study 26133902 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 125
Study 23419916 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping Method with convolutions in neutral position (10-15% tension, treated muscles in stretching position)
Number of subjects: 148
Study 23419916 — intervention group
Group type: COMPARATOR
Intervention: Kinesio Taping without convolutions in neutral (0% tension, treated muscles in resting position)
Number of subjects: 148
Study 21200334 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare Metal Stent (BMS)
Number of subjects: 97
Study 21200334 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Eluting Stent
Number of subjects: 97
Study 21200334 — intervention group
Group type: COMPARATOR
Intervention: Drug-Eluting Stent (DES)
Number of subjects: 97
Study 18506009 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery graft
Number of subjects: 142
Study 18506009 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein graft
Number of subjects: 142
Study 16680486 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic police (exposed to urban pollutants)
Number of subjects: 100
Study 16680486 — intervention group
Group type: COMPARATOR
Intervention: Controls (not exposed to urban pollutants)
Number of subjects: 100
Study 12540632 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Peptide (600 nmol/24 h, four doses s.c.)
Number of subjects: 49
Study 12540632 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Peptide
Number of subjects: 49
Study 12540632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 11712303 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine administered intravenously (single dose over 2 minutes)
Number of subjects: 31
Study 8886554 — intervention group
Group type: EXPERIMENTAL
Intervention: tolrestat
Number of subjects: 738
Study 1813733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (1.5 g single dose)
Number of subjects: 200
Study 1813733 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (2 g triple dose)
Number of subjects: 200
Study 6181113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragweed allergoid administered in a clustered regimen
Number of subjects: 0
Study 6181113 — intervention group
Group type: COMPARATOR
Intervention: Placebos in a clustered regimen
Number of subjects: 0
Study 6181113 — intervention group
Group type: COMPARATOR
Intervention: Unaltered ragweed extract (allergen) in a weekly regimen
Number of subjects: 0
Study 31858126 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (intramuscular injections every 2 weeks for 22 weeks)
Number of subjects: 64
Study 31858126 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intramuscular injections every 2 weeks for 22 weeks)
Number of subjects: 64
Study 30506519 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 226
Study 30506519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 28929513 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 87
Study 26531092 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable composite with adhesive system (Tetric EvoFlow)
Number of subjects: 4
Study 26531092 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly filled pit-and-fissure sealant (Fissurit FX)
Number of subjects: 4
Study 26531092 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly filled nano-hybrid pit-and-fissure sealant (Grandio Seal)
Number of subjects: 4
Study 26531092 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive flowable composite (Vertise Flow)
Number of subjects: 4
Study 24148053 — intervention group
Group type: EXPERIMENTAL
Intervention: Home to Stay
Number of subjects: 330
Study 24148053 — intervention group
Group type: COMPARATOR
Intervention: Standard shelter services
Number of subjects: 330
Study 21295880 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF) - 1.1Gy+2.0Gy/day, 5days/week for 4.5weeks, total dose 68Gy
Number of subjects: 750
Study 21295880 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF) - 2Gy/day, 5days/week for 7 weeks, total dose 68Gy
Number of subjects: 750
Study 21295880 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF)
Number of subjects: 750
Study 19275947 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referred recruitment strategy
Number of subjects: 0
Study 19275947 — intervention group
Group type: COMPARATOR
Intervention: Outreach recruitment strategy
Number of subjects: 0
Study 19275947 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive assessment
Number of subjects: 0
Study 19275947 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated assessment
Number of subjects: 0
Study 16917558 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal cauterization with outfracture
Number of subjects: 20
Study 16917558 — intervention group
Group type: COMPARATOR
Intervention: Submucosal cauterization without outfracture
Number of subjects: 20
Study 16917558 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 14961966 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonated autohemotherapy (O3‐AHT) with ozone concentration of 50 micro g/ml
Number of subjects: 12
Study 14961966 — intervention group
Group type: COMPARATOR
Intervention: Control (autohemotherapy with oxygen)
Number of subjects: 12
Study 11098980 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 42
Study 11098980 — intervention group
Group type: COMPARATOR
Intervention: Control (no inhaled NO)
Number of subjects: 42
Study 8342093 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium insufflation
Number of subjects: 20
Study 8342093 — intervention group
Group type: COMPARATOR
Intervention: CO2 insufflation
Number of subjects: 20
Study 3523663 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms terbutaline in one inhalation
Number of subjects: 12
Study 3523663 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 micrograms terbutaline in four inhalations taken in rapid succession
Number of subjects: 12
Study 3523663 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 micrograms terbutaline in four inhalations taken with an intervening time interval of 30 min
Number of subjects: 12
Study 3523663 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms terbutaline
Number of subjects: 12
Study 3523663 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 or 3 X 125 micrograms terbutaline with an intervening time interval of 30 min
Number of subjects: 12
Study 31978126 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) - 30 breaths twice-daily at 50% of maximal inspiratory pressure (MIP) for 8 weeks
Number of subjects: 37
Study 31978126 — intervention group
Group type: COMPARATOR
Intervention: Otago Exercise Program (OEP) - Resistance and mobility exercises for 60 minutes, twice-weekly for 8 weeks
Number of subjects: 37
Study 28857451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg/d
Number of subjects: 621
Study 28857451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg/d
Number of subjects: 621
Study 28857451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 621
Study 27731956 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block after induction of general anesthesia
Number of subjects: 60
Study 27731956 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 60
Study 25341356 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing Injection 50 mL Bid
Number of subjects: 56
Study 25341356 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 56
Study 21924397 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of peritoneum
Number of subjects: 533
Study 21924397 — intervention group
Group type: COMPARATOR
Intervention: Nonclosure of peritoneum
Number of subjects: 533
Study 19959538 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg/kg rFVIIa
Number of subjects: 841
Study 19959538 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 microg/kg rFVIIa
Number of subjects: 841
Study 19959538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 841
Study 19959538 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (combined)
Number of subjects: 841
Study 19317950 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic agents
Number of subjects: 0
Study 16002493 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation program (4 physical therapy sessions)
Number of subjects: 145
Study 16002493 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy-supervised rehabilitation program (17 physical therapy sessions)
Number of subjects: 145
Study 12781412 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of Tc-99m labelled albumin particles before sterilization
Number of subjects: 10
Study 12781412 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of Tc-99m labelled albumin particles after sterilization
Number of subjects: 10
Study 10573447 — intervention group
Group type: EXPERIMENTAL
Intervention: Agitated Behavior in Dementia scale (ABID)
Number of subjects: 148
Study 8756029 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva collected with the Omni‐SAL device tested with GACELISA
Number of subjects: 325
Study 8756029 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional serum Western blot kit
Number of subjects: 325
Study 8756029 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva collection method
Number of subjects: 325
Study 1542501 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug intake during pregnancy (excluding pregnancy supplements)
Number of subjects: 10698
Study 1542501 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal support therapy
Number of subjects: 10698
Study 1542501 — intervention group
Group type: EXPERIMENTAL
Intervention: Human teratogenic drugs
Number of subjects: 10698
Study 1542501 — intervention group
Group type: COMPARATOR
Intervention: General drug use during pregnancy
Number of subjects: 10698
Study 3890282 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (300 mg twice daily for five days)
Number of subjects: 20
Study 3890282 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (two tablets twice daily for five days)
Number of subjects: 20
Study 30605517 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 69
Study 30605517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 69
Study 30605517 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness Meditation (MM)
Number of subjects: 69
Study 29273691 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtemporal approach
Number of subjects: 47
Study 29273691 — intervention group
Group type: COMPARATOR
Intervention: Transsylvian approach
Number of subjects: 47
Study 29273691 — intervention group
Group type: EXPERIMENTAL
Intervention: Left side of surgery
Number of subjects: 47
Study 29273691 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both approaches)
Number of subjects: 47
Study 27029912 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) (n = 48)
Number of subjects: 96
Study 27029912 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT) (n = 48)
Number of subjects: 96
Study 27029912 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CBT)
Number of subjects: 96
Study 24162138 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stage laparoscopic CBD exploration and cholecystectomy (group 1)
Number of subjects: 168
Study 24162138 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP) for endoscopic extraction of CBD stones followed by laparoscopic cholecystectomy (group 2)
Number of subjects: 168
Study 22805100 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/d oral prednisone for 14 days with a 5‐day taper (121 patients)
Number of subjects: 250
Study 22805100 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 IT doses for 14 days of 40 mg/ml methylprednisolone (129 patients)
Number of subjects: 250
Study 20393355 — intervention group
Group type: EXPERIMENTAL
Intervention: Under-18 players
Number of subjects: 45
Study 20393355 — intervention group
Group type: COMPARATOR
Intervention: Under-20 and Senior players
Number of subjects: 45
Study 20393355 — intervention group
Group type: COMPARATOR
Intervention: Senior players
Number of subjects: 45
Study 20393355 — intervention group
Group type: COMPARATOR
Intervention: Yo-Yo intermittent recovery test (Yo-Yo IR1)
Number of subjects: 45
Study 20393355 — intervention group
Group type: EXPERIMENTAL
Intervention: Point guards
Number of subjects: 45